Profitable one year post-launch, YUTREPIA's commercial trajectory is the thesis — SSc-RP expansion is the upside option if Phase 2a data hold

Liquidia is a commercial-stage biopharmaceutical company whose approved lead product YUTREPIA treats pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, conditions for which it gained regulatory approval in June 2025.

YUTREPIA reached $170.4M in Q2 2026 net product sales, its fourth consecutive profitable quarter, within roughly a year of its June 2025 approval for PAH and PH-ILD. The expansion case rests on whether Phase 2a RE-WARM data support advancing into SSc-RP, an orphan indication with no approved therapy, and whether L606 succeeds in the Re-Spire pivotal study for PH-ILD. Seralutinib (Gossamer Bio) competes in both PAH and PH-ILD with a distinct inhaled mechanism, representing the primary commercial threat to YUTREPIA's patient share.